How do you choose between adjuvant PCV vs temozolomide in high risk oligodendroglioma with IDH mutation and 1p/19q co deletion?
NCCN lists PCV as category 1 (and now with analysis in Abstract 2002 from ASCO 2019 showing benefit in IDH mutated), and temozolomide as 2B, yet temozolomide is commonly used in practice.
Answer from: Medical Oncologist at Academic Institution
In our practice, we typically offer procarbazine/lomustine (with or without vincristine) to all patients with high risk oligodendroglioma, IDH mutated, 1p/19q codeleted. Temozolomide based on the Stupp regimen is used as an alternative when there are specific concerns for PCV related toxicity or str...
Comments
Radiation Oncologist at Radiant Oncology @Sani H. Kizilbash - Thank you for this reply. Do ...
Medical Oncologist at Mayo Clinic Not yet. Accrual is still incomplete. So, CODEL is...
@Sani H. Kizilbash - Thank you for this reply. Do ...
Not yet. Accrual is still incomplete. So, CODEL is...